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A B S T R A C T   
The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) 
remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and 
type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex 
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karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in 
this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corre-
sponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying kar-
yotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome 
in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), inde-
pendently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Addi-
tional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that 
could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel tar-
geted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.   
1. Introduction 
Genetic information in acute lymphoblastic leukemia (ALL) has long 
been obtained via conventional cytogenetics in clinical practice. Kar-
yotyping performed at diagnosis in childhood and adult B-cell precursor 
ALL (BCP-ALL) patients has allowed to identify recurrent abnormalities 
with prognostic relevance [1–4]. This is particularly true for primary 
genetic events such as t(9;22)(q34;q11.2), t(4;11)(q21;q23), t(12;21) 
(p13;q22) or t(1;19)(q21;p13.3) [1–4], and numerical chromosomal 
changes like low hypodiploidy/near triploidy, high hyperdiploidy [1,3, 
5], and complex karyotypes (CK) [1–4]. In contrast, widely accepted 
classification based only conventional cytogenetics is still missing for 
T-ALL. Moreover, the cut-off set in ≥5 cytogenetic abnormalities to 
define CK in BCP-ALL, might not be appropriate for T-ALL, since in other 
leukemias such as acute myeloid leukemia (AML) and myelodysplastic 
syndromes, a different number of cytogenetic lesions is used for the 
definition of CK associated with adverse patient outcomes [6–8]. 
Few attempts have been made in T-ALL to assess the prognostic 
impact of conventional karyotyping, based on large cohorts of homo-
geneously treated patients. In a study from the Pediatric Oncology 
Group only a normal karyotype and t(10;14)(q24;q11) were associated 
with a better prognosis in childhood T-ALL [9]. In turn, CK defined ac-
cording to the Moorman’s criteria [1], was associated with a poorer 
overall survival (OS) in a large study (n = 356 adult cases) by the UKALL 
XII/ECOG Group [10]. Lastly, the Nordic study showed that only 
infrequent TCR rearrangements were associated with a poorer prognosis 
in pediatric T-ALL [11]. A major challenge in developing a cytogenetic 
classification with prognostic significance for T-ALL is the rarity of the 
disease. In addition, while many recurrent abnormalities are rather 
infrequent, others are better detected by genomic techniques, including 
some recurrent primary alterations in TAL1, LMO2 and TLX3 tran-
scription factors, that have been associated with prognostic value in 
pediatric T-ALL patients [12]. 
Here we investigated the prognostic impact of cytogenetic data in a 
large series of 216 adult T-ALL patients treated within two consecutive 
minimal residual disease (MRD)-oriented trials from the Spanish 
PETHEMA (Programa Español de Tratamientos en Hematología) group. 
Our goal was to assess the potential usefulness of karyotypic data to 
identify high-risk adult T-ALL patients, and to further dissect the po-
tential underlying molecular alterations. 
2. Methods 
2.1. Patient cohort 
A total of 216 patients diagnosed with T-ALL according to the WHO 
criteria and treated within two consecutive MRD-oriented high-risk 
adults ALL protocols (ALL-HR-2003 [from 2003 to 2012, 
NCT00853008], [2011 to 2019, NCT01540812]) were analyzed. The 
immunological T-ALL subtypes were defined according to the European 
Group for the Immunological Characterization of Leukemias (EGIL) 
criteria [13], and the WHO [14] criteria was used to identify early T-cell 
precursor (ETP)-ALL, as previously described [15]. Treatment protocol 
schedules have been described elsewhere [16,17]. Briefly, in the 
ALL-HR-2003 trial the response to induction chemotherapy was evalu-
ated by cytomorphology and flow cytometry. Good responders -<5 % 
blasts (cytologic CR), and MRD ≤ 0.1 %- proceeded to consolidation 
chemotherapy, and whenever a good MRD response was maintained 
(MRD ≤ 0.05 %) they followed maintenance chemotherapy treatment. 
Poor responders (> 5 % blasts and/or MRD ≥ 0.1 %) received intensi-
fication of induction treatment, followed by allogeneic-hematopoietic 
stem cell transplantation (Allo-HSCT). Poor responders after consoli-
dation treatment (≥ 0.05 %) were also allocated to allo-HSCT. MRD 
assessment by flow cytometry was partially centralized in the 
ALL-HR-03 protocol. In the ALL-HR-11 trial the treatment allocation was 
exclusively based on fully centralized flow cytometry (MRD cut-off of 
≤0.1 % for good responders after induction treatment and MRD cut-off 
of ≤0.01 % for good responders after consolidation treatment), using the 
EuroFlow guidelines, as previously described [18]. 
2.2. Karyotyping 
Bone marrow (BM) and/or peripheral blood (PB) samples were 
processed at the institution-of-origin laboratories using standard cyto-
genetic methods, and karyotypes were reported according to the Inter-
national System for Human Cytogenetic Nomenclature [19]. 
Cytogenetic data were compiled and centrally analyzed. Karyotypes 
with ≥15 metaphases without abnormalities were classified as normal 
karyotypes (NK), whereas cases with <15 normal metaphases or with no 
growth of leukemic cells were considered to be non-evaluable (NE). Any 
additional genetic data coming from FISH analysis, was not considered 
in the genetic classification. Monosomal karyotype (MK) was defined 
according to Breems et al. definition [20], and the number of karyotypic 
abnormalities was assessed according to the criteria of Chu et al. [21]. 
Conventional CK included cases with ≥5 unrelated chromosomal ab-
normalities [1] and hyperdiploidy was defined as >46 chromosomes 
without structural abnormalities. 
2.3. Next generation sequencing (NGS) 
T-ALL cases with available DNA obtained at diagnosis (n = 30) from 
the PETHEMA cohort, were analyzed by target deep sequencing (TDS) 
using a NGS panel (NGSp) designed at the Agilent SureDesing platform 
(Agilent Technologies, Santa Clara, CA), from which 5 DNA corre-
sponded to patients with ≥3 CK and 25 to patients with <3 alterations. 
The genes included in the panel are listed in Supplemental Table 1. To 
increase genomic data of cases with ≥3 CK, we took advantage of the 
genomic data generated at the MLL Munich Leukemia Laboratory 
(Munich, Germany) and we included 38 T-ALL cases from the MLL 
cohort from which whole genome sequencing (WGS) data was available. 
Main patient characteristics are shown in Supplemental Table 2. We 
select adult patients in the same age range as the Spanish cohort [15;60]. 
We distributed them in cases with ≥3 CK or <3 alterations, similarly as 
we did for the PETHEMA cohort, taking only into account cytogenetic 
data. Briefly, WGS libraries were prepared with the TruSeq PCR free 
library prep kit. Hundred-fifty base pair (bp) paired-end sequences were 
generated on a NovaSeq 6000 or HiSeqX instrument (Illumina, San 
Diego, CA) with 100x coverage. NGSp libraries were prepared with the 
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SureSelect XT HS (Agilent technologies) chemist. Pooled libraries were 
sequenced 2 × 75bp paired-end sequences on a Miseq instrument 
(Illumina) at 300X mean depth. Fastq files from WGS and TDS were 
aligned to the hg19 reference genome. The Illumina tumor/unmatched 
normal workflow was used for the WGS variant calling. Here, a mixture 
of genomic DNA from multiple anonymous donors (n = 6) was used as 
normal controls. TDS variant calling was performed using Samtools4 
(version 1.10, http://www.htslib.org/) and VarScan2 (version 2.4.0, htt 
ps://dkoboldt.github.io/varscan/). Exonic and splice-site variants ob-
tained by WGS and TDS were annotated using ANNOVAR (version 2018- 
04-16, http://annovar.openbioinformatics.org/en/latest/). Poly-
morphisms described in population databases (1000Genomes, ExAC, 
gnomAD and Exome Variant Server) with a calculated mean population 
frequency > 0.1 % were excluded from further analyses. Annotated 
variants were selected after filtering out calls according to the following 
criteria: coverage <30X, <8 alternative reads or variant allelic fraction 
(VAF) <5 %. Finally, selected variants were annotated using DBNSFP in 
silico predictors (SIFT, Polyphen2, LRT, MutationTaster, Muta-
tionAssessor, FATHMM, PROVEAN, VEST3, MetaSVM and MetaLR), 
excluding benign predicted variants (>5 predictor scores considering a 
variant as benign). 
2.4. Outcome variables and statistical analysis 
Overall survival (OS) was measured from the time of diagnosis to the 
time of death or last follow-up. Event-free survival (EFS) was calculated 
from diagnosis to last follow-up, considering failure, relapse or death by 
any cause as events. Cumulative incidence of relapse (CIR) was 
measured from first CR date to relapse or last follow-up, being non- 
relapse mortality the competing event. Main demographic, clinical, 
laboratory and genetic characteristics were described. Comparisons 
between groups were performed by the chi-square test or Fisher’s exact 
test (categorical variables) and the median test (numerical variables). 
EFS and OS curves were plotted by the Kaplan-Meier method and were 
compared by the log-rank test. Estimates of CIR were calculated using 
cumulative incidence functions and compared using Gray’s test. Multi-
variable analyses were performed using the Cox proportional hazards 
model for OS and EFS, and the Fine and Gray model for CIR. The sig-
nificance level was set at P < .05. All statistical analyses were carried out 
with the SPSS package v24.0 and the R 3.6.3 software. 
3. Results 
From a total of 216 treated adults, 207 were included in the study 
(100 from the ALL-HR-2003 and 107 from the ALL-HR-11 trials). Lack of 
karyotype (n = 5), lack of follow-up (n = 2), protocol violation (n = 1) 
and T-cell lymphoma (n = 1) were the reasons of exclusion. Detailed 
patient characteristics at diagnosis and at follow-up are described in 
Table 1. Overall, 74/207 (36 %) showed a normal karyotype (NK) and 
68/207 (33 %) had non-evaluable (NE) cytogenetic results. Patients 
with abnormal karyotypes (65/139, 47 %) were grouped as follows: 1) 
structural abnormalities (SA) only, (38/139 [29 %]); 2) structural +
numerical abnormalities (SNA) (21/139 [15 %]; and 3) hyperdiploidy 
only (6/139 [4 %]). In addition, karyotypes were classified according to 
classical CK (≥5 abnormalities, 10/139 [7 %]) and MK (10/139 [7 %]). 
Chromosome 14 was the most frequently lost chromosome (n = 3) and 
no cases only showing chromosomal losses were detected in our cohort. 
The percentages of NK, NE karyotypes, and CK, were similar to those 
reported by others [10]. Previously reported primary cytogenetic al-
terations involving T-ALL-associated transcription factors such as 
TLX1/TLX3 and LMO [22–25] were also identified at very low fre-
quencies (Table 1). Of note, patients carrying the TLX1/TLX3 and LMO2 
alterations belonged to the SA category and the genetic event (rear-
rangement) was mostly found as unique abnormality or it was associated 
with another single alteration. In turn, 7/11 (64 %) of cases with del(6q) 
were found as a single or as a partner alteration. In parallel, karyotypes 
were also classified according to the number of chromosomal alter-
ations, independently of their nature (Supplemental Table 3). 
Based on the above main cytogenetic subgroups, we investigated the 
potential clinical impact of this cytogenetic classification on patient 
outcome (OS, EFS and CIR). Overall, patients with NE karyotype had a 
very similar outcome to cases with NK; in contrast, the outcome of NE 
and NK cases was clearly better than that of patients with an abnormal 
karyotype in terms of EFS, but not of OS and CIR (Supplemental Fig. 1). 
These findings suggest the absence of poor prognosis karyotypes among 
NE cases. Despite this, cases with NE karyotypes were excluded from 
further prognostic analyses. In such analyses, specific cytogenetic sub-
groups such as MK and CK (≥5 cytogenetic abnormalities) were asso-
ciated with poor OS (3y prob [CI 95 %] of 15 % [0 %; 40 %] for MK vs 51 
% [41 %; 61 %] for non-MK cases, p = 0∙012; and of 13 % [0 %; 36 %] 
for ≥5 CK vs 51 % [41 %; 61 %] for other cases with <5 chromosomal 
alterations, p = 0∙012), EFS (1y prob [CI 95 %] of 40 % [10 % ; 70 %] 
for MK vs 64 % [55 %; 73 %] for non-MK, p=<0∙001; and of 40 % [10 
%; 70 %] for ≥5 CK vs 64 % [55 %; 73 %] for those with <5 cytogenetic 
alterations, p = 0∙004), and CIR (1y prob [CI 95 %] of 88 % [6 %; 99 %] 
for MK vs 43 % [33 %; 53 %] for non-MK, p = 0∙001; and of 56 % [16 %; 
83 %] for ≥5 CK vs 45 % [34 %; 55 %] for those with <5 chromosomal 
Table 1 
Demographic, clinical, laboratory and genetic features of adult T-ALL patients 
included in this study.   
Patient distribution 
Clinical and laboratory features  
Age (yrs)* 32 [15; 60] 
Female/male ratio 54/153 
Lymph node enlargement 109/183 (60 %) 
Splenomegaly 72/201 (36 %) 
Hepatomegaly 47/198 (24 %) 
Mediastinal mass 96/205 (47 %) 
WBC count (x109/L)* 40.8 [0.6; 842] 
CNS involvement 20/198 (10 %) 
Immunophenotype  
Unclassified 19 (9 %) 
ETP-ALL 35 (17 %) 
Pre-T 35 (17 %) 
Cortical 79 (38 %) 
Mature 39 (19 %) 
T-ALL genetic hallmarks  
TLX1 3/207 (1.5 %) 
TLX3 1/207 (0.5 %) 
TAL1 4/207 (2 %) 
LMO2 2/207 (1 %) 
KMT2A rearranged 3/207 (2 %) 
TCR rearranged 1/207 (0.5 %) 
del(6q) 11/207 (5 %) 
CDKN2A/B gene deletion 31/53 (58 %) 
TCRG gene deletion 24/31 (77 %) 
Treatment  
Chemotherapy 97/139 (70 %) 
Allo-HSCT 42/139 (30 %) 
Response to treatment  
Slow response at day +14 90/186 (48 %) 
Nº of induction cycles to CR:  
One induction 156/187 (83 %) 
Two inductions 31/187 (17 %) 
CR 187/207 (90 %) 
MRD day +35 < 0.1 % 125/162 (77 %) 
MRD day +35 < 0.01 % 90/154 (58 %) 
Results expressed as number of cases (percentage) or * as a median [range]. 
Specific alterations detected included: TLX1, 3 cases with t(10;14); TLX3 1 case 
with t(5;7)(q35;q21); TAL1 1 case with t(1;14)(p32;q21) and t(1;12)(p32;q13), 
and 2 cases with del(1)(p32); LMO2, 2 cases with t(11;14)(p13;q11). 
MRD values were considered only for those patients that reached CR. Yrs: years; 
WBC: white blood cells; CNS: central nervous system; ETP-ALL: early T-cell 
precursor acute lymphoblastic leukemia; CR: complete remission; MRD: mini-
mal residual disease; d+14: fourteen days after starting induction treatment; 
d+35: thirty-five days after starting induction treatment; Allo-HSCT: allogeneic 
hematopoietic stem cell transplantation. 
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changes, p = 0∙013), as previously reported by others [3,10]. Patients 
with MK and CK (≥5 abnormalities) were both included in the large SNA 
cytogenetic group (15 % T-ALL cases) and retained their adverse clinical 
outcome when compared to non-SNA patients (Supplemental Fig. 2). In 
contrast, hyperdiploidy and SA did not show an adverse impact on T-ALL 
patient outcome (data not shown). Further investigation of the prog-
nostic impact of the number of chromosomal alterations independently 
of their nature, showed that the presence of ≥3 cytogenetic abnormal-
ities (≥3 CK) in our adult T-ALL patients, already conferred a poorer 
prognosis in terms of OS, EFS and CIR, similar to that of cases showing a 
classical CK with ≥5 cytogenetic alterations (Fig. 1 and Supplemental 
Table 3). Of note, karyotypes with ≥3 abnormalities accounted for 16 % 
of all evaluable karyotypes (22/139), which would represent the largest 
poor prognosis cytogenetic subgroup identified so far in T-ALL. All cases 
(n = 4) in which chromosomal rearrangements or deletion involving the 
TAL1 transcription factor were detected, were included in this category, 
in addition to patients with MK and CK (≥5 abnormalities) (Supple-
mental Table 4). Other variables than the new ≥3 CK cytogenetic sub-
group, the MK, ≥5 CK and SNA cytogenetic category, that showed a 
significant impact on patient outcome, included treatment protocol, age, 
white blood cell (WBC) count, and ETP-ALL (Table 2). Multivariate 
analysis confirmed the independent adverse prognostic value of the 
presence of ≥3 cytogenetic abnormalities at diagnosis, for all the three 
prognostic end-points evaluated (Table 2). Importantly, karyotypes with 
≥3 abnormalities retained their adverse prognostic impact also when 
MRD data obtained at the end of induction therapy (day+35) were 
included in the multivariate analyses (Table 3). Of note, in our cohort 
having ≥3 CK was the only risk factor, together with age, with an in-
dependent predictive value to identify at diagnosis patients that will 
relapse (Table 2). In turn, the ≥3 CK together with the WBC count at 
diagnosis and MRD status at day+35, were the only independent pre-
dictors for OS and EFS (Tables 2 and 3). Other variables such as the ETP 
immunophenotype did not prove to be independent predictors of patient 
outcome in the multivariate analysis. No relationship was found be-
tween ≥3 CK and other patient characteristics such as age, WBC count, 
CNS involvement and ETP-ALL. 
In order to analyze the underlying reasons for the poor prognosis of 
≥3 CK in adult T-ALL, we investigate the potential association of ≥3 CK 
with response to therapy. Despite the similar initial response to therapy 
(day+14) between ≥3 CK and other T-ALL cases (p = 0∙167), ≥3 CK 
patients showed a significantly lower end-induction CR rate (77 % vs. 94 
% for the remaining T-ALL, p = 0∙032). Of note, 2/5 ≥ 3 CK patients 
who did not reach CR at the end of induction therapy died due to toxicity 
whereas the other 3/5 did not continue the protocol because of re-
fractory disease. Among those patients that achieved CR, a similar 
number of induction cycles were administered for ≥3 CK vs other T-ALL 
cases. Consistent with the lower CR rate observed for ≥3 CK patients, 
lack of end-induction MRD response (>0.01 %) was more frequently 
observed among patients with ≥3 CK than the remaining patients (65 % 
vs. 40 %, p = 0∙06). However, no differences in the frequencies of 
chemotherapy or allo-HSCT allocation at the end of consolidation 
therapy were observed on comparison of patients within ≥3 CK with the 
remaining. 
In order to better understand the molecular mechanisms underlying 
the poorer outcome of ≥3 CK patients, molecular studies by NGS were 
performed. T-ALL cases with available DNA obtained at diagnosis (n =
30) from the PETHEMA cohort, were analyzed by TDS. To increase 
genomic data of cases with ≥ 3 CK, we included additional 38 T-ALL 
cases from the MLL cohort from which WGS data was available. Selec-
tion criteria of the T-ALL cases from the MLL cohort included in the 
study and homogenization and standardization of NGS data analysis is 
described in material and methods section. Overall, we observed that the 
mutational profile identified in the T-ALL patients analyzed was similar 
to those previously reported by others (Fig. 2) [26,27]. Interestingly, 
Fig. 1. Impact of karyotypes with ≥3 vs 0-2 cytogenetic alterations for OS (A), EFS (B) and CIR (C) at 3-year probability in the PETHEMA cohort.  
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three distinct genetic signatures were identified manually, when 
comparing ≥3 CK vs. <3 CK patient groups. Thus, there were genes that 
were not differentially mutated in ≥3 CK vs other T-ALL cases. These 
included mutations in the NOTCH1/FBXW7 signaling pathway (53 % for 
≥3 CK vs. 67 % for other T-ALL patients; p = 0∙31) and in PHF6 (35 % 
for ≥3 CK vs. 22 % for other T-ALL cases; p = 0∙26) gene. A subset of 
genes that was found to be non-mutated in ≥3 CK patients while 
mutated in other T-ALL cases, such as genes involved in the 
JAK1/3/AKT1 signaling pathway (0 % for ≥3 CK vs. 25 % for other 
T-ALL cases, p = 0∙02) and genes related to DNA methylation, e.g. the 
Table 2 













HR (95 %CI) HR (95 %CI) HR (95 %CI) 
Univariate 
analysis          
ALL-HR2003 
protocol 
100/207 1.62 (1.05;2.5) 0.028 100/207 1.43 (0.97;2.09) 0.069 89/187 1.18 (0.73;1.89) 0.500 
Age* 207 1.01 (0.99;1.02) 0.456 207 0.99 (0.98;1.01) 0.897 /87 0.97 (0.95;0.99) 0.022 




0.028 207 1.002 
(1.000;1.003) 
0.032 187 1.001 
(0.999;1.003) 
0.480 
CNS involvement 20/198 1.16 (0.56;2.41) 0.681 20/198 1.24 (0.66;2.3) 0.498 16/178 1.08 (0.47;2.48) 0.850 
ETP-ALL 35/188 1.83 (1.11;3.01) 0.018 35/188 1.67 (1.05;2.66) 0.029 27/170 1.27 (0.69;2.33) 0.440 
CK (≥3 
alterations) 
22/139 3.04 (1.67;5.51) <0.001 22/139 2.96 (1.68;5.2) <0.001 17/127 2.76 (1.41;5.4) 0.003 
CK (≥5 
alterations) 
10/139 2.52 (1.19;5.31) 0.016 10/139 2.72 (1.34;5.54) 0.006 9/127 2.57 (1.05;6.3) 0.038 
MK 10/139 2.53(1.19;5.35) 0.015 10/139 3.23 (1.64;6.35) 0.001 8/127 3.67 (1.73;7.77) <0.001 
SNA 21/139 2.30 (1.27;4.19) 0.006 21/139 3.01 (1.75;5.17) <0.001 17/127 3.23 (1.81;5.75) <0.001 
SA 38/139 1.23 (0.72;2.09) 0.441 38/139 1.14 (0.69;1.82) 0.595 35/127 0.95 (0.50;1.79) 0.860  
Multivariate 
analysis          
ALL-HR2003 
protocol 
– – NS 
(0.75) 
– – NS 
(0.29) 
– NA NA 
Age* – NA NA – NA NA – 0.97 (0.94;0.99) 0.032 




0.001 – 1.004 
(1.002;1.005) 
<0.001 – NA NA 
ETP-ALL – – NS 
(0.33) 
– – NS 
(0.33) 
– – – 
CK (≥3 
alterations) 
– 3.37 (1.76;6.46) <0.001 – 3.43 (1.86;6.31) <0.001 – 2.91 (1.48;5.5) 0.002  
* Age and WBC were considered as continuous variables. HR: Hazard ratio; CI: confidence interval; OS: overall survival; EFS: event-free survival; CIR: cumulative 
incidence of relapse; WBC: white blood cell; ETP-ALL: early T-cell precursor ALL; CNS: central nervous system; CK: complex karyotype; SNA: structural + numerical 
abnormalities; SA: only structural alterations.  
Table 3 
Univariate and multivariate analysis of prognostic factors for OS and CIR in adult T-ALL patients including end-induction MRD level.   
N (positive/evaluable) 
OS 
P value N (positive/evaluable) 
CIR 
P value 
HR (95 %CI) HR (95 %CI) 
Univariate analysis       
ALL-HR2003 protocol 89/187 1.72 (1.05;2.82) 0.031 89/187 1.18 (0.73;1.89) 0.500 
Age* 187 0.99 (0.98;1.02) 0.760 187 0.97 (0.95;0.99) 0.022 
WBC count (x109/L)* 187 1.002 (1.000;1.004) 0.054 187 1.001 (0.999;1.003) 0.480 
CNS involvement 16/178 0.98 (0.39;2.43) 0.960 16/178 1.08 (0.47;2.47) 0.850 
ETP-ALL 27/170 1.47 (0.79;2.70) 0.219 27/170 1.27 (0.69;2.33) 0.440 
CK (≥3 alterations) 17/127 2.64 (1.30;5.36) 0.007 17/127 2.76 (1.41;5.38) 0.003 
CK (≥5 alterations) 9/127 2.81 (1.26;6.27) 0.012 9/127 2.57 (1.05;6.30) 0.038 
MK 8/127 2.53 (1.07;5.96) 0.034 8/127 3.67 (1.73;7.78) <0.001 
SNA 17/127 2.07 (1.03;4.16) 0.040 17/127 3.23 (1.81;5.75) <0.001 
SA 35/127 1.32 (0.74;2.37) 0.348 35/127 0.95 (0.50;1.79) 0.860 
MRD day +35 (≥0.1 %) 37/162 1.94 (1.11;3.37) 0.019 37/162 1.36 (0.76;2.44) 0.300 
MRD day +35 (≥0.01 %) 64/154 2.30 (1.30;4.08) 0.004 64/154 1.20 (0.71;2.05) 0.490  
Multivariate analysis       
ALL-HR2003 protocol – – NS (0.316) – NA NA 
Age* – NA NA – 0.97 (0.94;0.99) 0.032 
WBC count (x109/L)* – 1.005 (1.002;1.009) 0.001 – NA NA 
ETP-ALL – – NS (0.807) – – – 
CK (≥3 alterations) – 4.17 (1.79;9.69) 0.001 – 2.91 (1.48;5.70) 0.002 
MRD day +35 (≥0.01 %) . 2.27 (1.12;4.60) 0.023 – NA NA  
* Age and WBC were considered as continuous variables. HR: Hazard ratio; CI: confidence interval; OS: overall survival; CIR: cumulative incidence of relapse; WBC: 
white blood cell; ETP-ALL: early T-cell precursor ALL; CNS: central nervous system; CK: complex karyotype; SNA: structural + numerical abnormalities; SA: only 
structural alterations; MRD: minimal residual disease.  
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DNMT3A (0 % for ≥3 CK vs. 10 % among other T-ALL cases: p = 0∙18) 
and TET2 (0 % for ≥3 CK vs. 6 % for other T-ALL patients; p = 0∙31) 
gene. These genes have been previously associated with an immature 
T-ALL immunophenotype [28]. Finally, a third group of genes that were 
mutated at greater frequencies in ≥3 CK patients vs other T-ALL cases, 
including the KMT2C (35 % vs 10 %, respectively; p = 0∙01), IL7R (29 % 
vs 8 %, respectively; p = 0∙02) and GATA3 (12 % vs 0 %, respectively; p 
= 0∙01) genes. 
4. Discussion 
Conventional cytogenetics is still a widely used technique in the 
diagnostic of ALL for the fast and robust identification of Ph+ ALL or 
KMT2A/AFF1 patients with important therapeutic consequences. How-
ever, with the irruption of high-throughput genomic techniques, the 
usefulness of conventional cytogenetics has been questioned, particu-
larly for T-ALL patients, due to the low number of cases with informative 
abnormalities (30 %) and the lack of a widely-accepted standard cyto-
genetic classification. This, together with the low prevalence of patients 
with T- vs BCP-ALL, has translated into a very limited information on the 
prognostic value of karyotyping, particularly among adult T-ALL. 
The prognostic impact of conventional cytogenetics was assessed in a 
large cohort of adult T-ALL patients treated with two sequential trails 
from the PETHEMA group. Our results show for the first time, that 
karyotype is a strong independent prognostic marker that can be ob-
tained already at diagnosis to predict outcome of adult-TALL patients. 
Specifically, the presence of ≥3 cytogenetic alterations was the most 
informative adverse prognostic factor for OS, EFS and CIR when T-ALL 
karyotypes were classified according to the number of cytogenetic al-
terations, using a well standardized method [21]. Karyotypes with ≥3 
abnormalities accounted for 16 % of all evaluable karyotypes, thereby 
representing the largest poor prognosis cytogenetic subgroup identified 
so far in T-ALL. However, it should be pointed out that the classification 
of adult T-ALL patients from this series according to previously defined 
primary cytogenetic events (gene rearrangements), was not possible due 
to the low number of cases in each of these subgroups (i.e. t(10;14); t 
(5;7)(q35;q21); t(1;14)(p32;q21); t(1;12)(p32;q13); del(1)(p32) or t 
(11;14)(p13;q11)). Underrepresentation of the primary genetic events 
in our cohort might be due to differences in the prevalence of these al-
terations in adult vs. childhood T-ALL, to the locally performed con-
ventional cytogenetics and to the lower sensitivity of cytogenetics vs, 
molecular techniques, among other reasons. 
Despite the above limitations, our results show that compared to 
BCP-ALL, a lower genetic complexity is required in adult T-ALL patients 
to define adverse complex karyotypes. Thus, complex karyotype with 
≥3 alterations is a marker of inferior outcome in terms of OS, EFS and 
CIR, independently of other prognostic features such as age, WBC count 
at diagnosis and the MRD status after induction therapy. The adverse 
prognostic impact of ≥3 CK together with age were the only indepen-
dent predictors for an impending relapse after starting therapy, ruling 
out the predictive value of MRD to identify patients with early relapse. 
This is probably due to the fact that while MRD could identify those 
patients at lower (MRD negative) vs high (MRD positive) risk of relapse, 
≥3 CK discriminated among the MRD positive patients those at risk of 
earlier recurrence of the disease. These results are of clinical relevance 
because in contrast to MRD results, karyotypic data are already available 
at diagnosis, which facilitates early risk stratification of the disease for 
early risk-adapted treatment (intensification) decisions. 
In order to better understand the mechanisms underlying the poorer 
prognosis of patients with ≥3 CK we investigated the reasons for their 
dismal outcome and the associated gene mutational profiles. Patients 
with ≥3 CK showed a significantly higher rate of refractoriness to in-
duction therapy used in the two PETHEMA protocols, together with a 
poorer clearance of blast cells, as reflected by lower rates of both CR and 
MRD negativity after induction therapy. Treatment intensification by 
allo-HSCT was not more prevalent in patients with ≥3 CK, possibly due 
to premature exclusion of these patients due to refractoriness or early 
relapse. Treatment resistance and tumor genetics have both been 
recurrently associated with specific gene mutational profiles in ALL [29, 
30]. Of note, genomic analysis performed combining NGS data revealed 
the presence of unique mutational profiles among ≥3 CK cases vs other 
T-ALL patients. These profiles consisted in a predominance of mutations 
in the KMT2C, GATA3 and IL7R genes, and absence of mutations 
involving genes of the JAK1/3/AKT1 signaling pathway and genes 
related to DNA methylation, such as the DNMT3A and TET2. Such 
mutational profile might contribute to explain the poorer outcome for 
≥3 CK patients. As an example, activating mutations in IL7R, confer 
glucocorticoid resistance and poor clinical outcome in childhood T-ALL 
[31]. Thus, IL7R works as biomarker of reduced steroid response, which 
could contribute to explain, at least in part, the increased resistance to 
treatment and the poorer blast clearance observed in patients with high 
genetic complexity (≥3 CK). In this sense, a recent report from the 
GRAALL cooperative group showed that patients with IL7Rp mutated 
T-ALL were slow-responders, with a high level of MRD in day-8 bone 
marrow, compared to unmutated cases, although no correlation was 
observed with response to prednisone [32]. 
Fig. 2. Mutational spectrum of ≥3 CK and <3 CK adult T-ALL patients. Genomic data from the PETHEMA (n = 30) and MLL (n = 38) cohorts are shown together. 
Global mutational frequency for each gene is shown on the left. Genes are grouped according the three signatures identified and ordered by frequency. Each colored 
square indicates a positive mutation for the indicated gene. Blue dark squares identify patients with ≥3 abnormalities. Light blue squares identify patients <3 CK. 
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In summary, here we propose a definition for CK in adult T-ALL 
based on the presence of ≥3 cytogenetic alterations, with important 
implications for improved risk stratification at diagnosis. In addition, we 
have shown that patients with ≥3 CK carry unique gene mutational 
profiles, that might benefit in the future from novel targeted therapies 
directed against the mutated genes (e.g. IL7R). Further studies in large 
series of adult T-ALL patients treated with similar and novel therapies 
are necessary to confirm our results. 
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